The PFA-SHAM trial and MANIFEST-US registry support the efficacy and safety of the increasingly used ablation modality.

EchoPrime was trained on more than 12 million videos; it’s now being tested clinically, with more data expected next year.

The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical ...

Quantifying blood flow instead of relying on angiography alone led to a change in diagnosis for 53% of patients.

In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers ...

The answer is very clear that if you have MI and preserved EF, there is no benefit of using a beta-blocker. Sripal Bangalore ...

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.” ...

The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.